# Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

> **NCT03275922** · PHASE3 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 374 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Placebo ZNS
- **DRUG:** ZNS

## Key facts

- **NCT ID:** NCT03275922
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2020-07-02
- **Final completion:** 2020-09-28
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2021-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275922, "Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03275922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*